Platelet activating factor or PAF-acether, which was identified as a 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (Demopoulos et al., 1979; Benveniste et al., 1979) , is a mediator in IgE-induced systemic anaphylaxis in rabbits (Benveniste et al., 1972; Henson & Pinckard, 1977) . During allergic and inflammatory reactions PAF-acether is released by leucocytes and macrophages (Siraganian & Ostler, 1971; Polonsky et al., 1980) . It has been shown to induce chemotaxis (Shaw et al., 1981) and degranulation of polymorphonuclear leucocytes , hypotension (McManus et al., 1980) and smooth-muscle contraction (Findlay et al., 1981) , but its most striking biological activity is its potency as a platelet stimulator, inducing aggregation and secretion responses in the nanomolar range (Vargaftig et al. 1982a; Chesney et al., 1982; Kloprogge et al., 1983) .
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Platelet agonists generally activate the cells via receptor-mediated processes. The identification of a specific receptor for PAF-acether is complicated by its hydrophobic nature, making it a component that easily penetrates biological membranes (Lumb et al., 1983) . Furthermore, exogenous PAFacether is metabolized by platelets, which probably implies uptake into the platelet and incorporation in still largely obscure metabolic pathways (Alam et al., 1983; Pieroni & Hanahan, 1983; Touqui et al., 1982) .
Early studies by Shaw & Henson (1980) demonstrated that PAF-acether lost its activity as a secretagogue after preincubation with rabbit platelets. This was interpreted as the first indication that PAF-acether could bind to platelets and that it activated the cells via a receptor-mediated process. Valone et al. (1982) , using 3H-labelled PAFacether, confirmed that human platelets bound PAF-acether and found two distinct types of binding sites differing about 37-fold in their affinity for PAF-acether.
The present report provides a detailed study of the kinetics of [311] PAF-acether binding to Vol. 223 human platelets. The results substantially deviate from the early findings by Valone et al. (1982) and, in addition, provide evidence for coupling between receptor occupancy and platelet activation, suggesting that platelets are activated by PAF-acether via receptor-mediated processes.
Materials and methods Chemicals
[3H]PAF-acether { 1-0-[l,2(n)-3H]hexadecyl/ octadecyl-2-acetyl-sn-glycero-3-phosphocholine; 91 .2Ci/mmol} and lyso-[3H]PAF-acether (1-0-[3H]octadecyl-sn-glycero-3-phosphocholine; 129 Ci/mmol) were purchased from Amersham International (Amersham, Bucks., U.K.). Nonradiolabelled PAF-acether and lyso-PAF-acether were from Calbiochem-Behring Corp. (La Jolla, CA, U.S.A.) and Bachem (Bubendorf, Switzerland) respectively. All ether phospholipids were stored at -20°C in toluene/ethanol (1:1, v/v) under N2. Before use, stock solutions were prepared by evaporating the solvent with N2 and dissolving the ether phospholipids in 0. 15M-NaCl, containing bovine serum albumin (2.5 mg/ml) (Organon Technika, Oss, The Netherlands). Yohimbine was obtained from Sigma, St. Louis, MO, U.S.A.; phentolamine from Ciba-Geigy, Basel, Switzerland, and prasozine from Pfizer, Brussels, Belgium.
Phospholipids used as references in t.l.c. studies were: phosphatidic acid (egg; Serdary Research Laboratories, London, Ontario, Canada), lysophosphatidylcholine (Applied Science Laboratories, Riviera Beach, PA, U.S.A.), phosphatidylserine, phosphatidylethanolamine, sphingomyelin, phosphatidylinositol and phosphatidylcholine (Supelco, Bellefonte, PA, U.S.A.), phosphatidylinositol 4,5-bisphosphate and phosphatidylinositol 4-monophosphate (Sigma).
Fibrinogen (KABI, Stockholm, Sweden) was made fibronectin-free by passage through a gelatin-Sepharose 4B column (Pharmacia, Uppsala, Sweden) (Engvall et al., 1978) in the presence of lOnM-6-aminohexanoic acid (Baker, Deventer, The Netherlands) and 1 mm-benzamidine hydrochloride (Sigma). After four dialyses against 40 vol. of Tyrode's buffer (Walsh, 1972) (12h, 4°C) , the fibrinogen solution was concentrated by dehydration with Sephadex G-200 (Pharmacia). Contamination with Factor VIII/von Willebrand factor was less than 0.015% on molar basis, as measured by enzyme immunoassay (Cejka, 1982) . Electrophoretic identification on SDS/(7.5%, w/v) polyacrylamide gels (Laemmli, 1970) under reducing conditions revealed a pure preparation consisting of Aoa-chains (M, 68 000), Bfi-chains (57 000) andychains (49000).
Platelet isolation
Venous blood from healthy volunteers was collected (with informed consent) directly into O.lvol. of 130mM-trisodium citrate. The donors claimed not to have taken any medicine during the 10 days before blood collection. After centrifugation (Omin, 200g, 22°C) the platelets were isolated by gel filtration (Sepharose 2B; Pharmacia) (Tangen et al., 1971) at room temperature in Ca2+-free Tyrode solution (Walsh, 1972) [3H]Phospholipid analysis In a few experiments, the incubation of gelfiltered platelets with [3H]PAF-acether was terminated by adding 3.6ml of methanol/chloroform (2: 1, v/v) to 1 ml of platelet suspension. The lipids were extracted as described by Bligh & Dyer (1959) , subjected to t.l.c. and separated on highperformance t.l.c. plates (Merck; no. 5641) using a basic solvent system of chloroform/methanol/aq. 20% (v/v) methylamine (30:18:5, by vol.) (Pieroni & Hanahan, 1983) . Lipid spots were located with I2 vapour. The material contained in the spots was collected and extracted in chloroform/methanol (2: 1, v/v) and the radioactivity was measured by standard methods. Recovery of the 3H was 60 ± 7% (mean+ S.D., n = 12).
Analysis ofplatelet responses
Aggregation of gel-filtered platelets induced by PAF-acether was measured by two techniques: firstly, by recording the change in light transmission at 22°C in a Payton dual-channel aggregation module (Payton Associates, Scarborough, Ontario, Canada) and secondly, by counting the disappearance of single platelets (Frojmovic et al., 1982) . For the latter technique, platelets were incubated with PAF-acether with or without fibrinogen (0.3mg/ml) under stirring and nonstirring conditions (22°C). The incubation was stopped by fixing the platelets in 9 vol. of a mixture of cold (0°C) 0.5% glutaraldehyde (Fluka, Buchs, Switzerland). The platelets were counted in a Platelet Analyzer 810 (Baker Instruments, Allentown, PA, U.S.A.) with apertures set at 3.2 and 16pm3. In unstimulated platelet suspensions 94.5+1.1% (mean+s.D., n= 11) of the total platelets were counted within these settings.
PAF-acether-induced fibrinogen binding was measured using '25I-labelled fibrinogen obtained with the Iodogen-labelling procedure in lodogencoated conical 3ml glass Mini Vials (Chrompack, Middelburg, The Netherlands) (Nieuwenhuizen et al., 1980) in three successive incubations of 20min each (0°C). 1251 was obtained from Amersham International. The 125I-fibrinogen was dialysed three times against 500vol. of non-radioactive KI (lOg/litre in 0.15M-NaCl) at 4°C for 12 h, followed by dialysis against 500vol. of Tyrode's buffer (12h, 4°C). Insoluble contaminants were removed by centrifugation (lOOOOg, 0min). Clottability, initiated with 5 units of thrombin (Roche, Basel, Switzerland)/ml, was >99% and the content of free 1251 was never more than 4.2% of the total 125I radioactivity. The specific activity of 1251-fibrinogen varied between 0.5 and 3.OCi/mmol. 1251-labelled fibrinogen was stored at -70°C and used within 3 weeks after preparation.
Changes in phosphoinositides and phosphatidic acid in platelets on stimulation with PAF-acether were measured according to a modification of the procedure described by Jolles et al. (1981) for rat brain cells. In short, platelet-rich plasma was labelled with 32p, (O.1mCi/ml, carrier-free, type NEX-054; New England Nuclear, Boston, MA, U.S.A.) for 60min at 37°C. The platelets were gelfiltered in Ca2+-free Tyrode's solution, without NaH2PO4, at 22°C and incubated with 0.5nM-PAF acether. The reaction was terminated after 20min by adding 2ml of chloroform/methanol/13M-HCl (100:50:1, by vol.; 0C). The lipids were extracted as described by Bligh & Dyer (1959) . Phospholipids were separated by highperformance t.l.c. and the radioactivity was measured as described by Jolles et al. (1981) . Results 
PAF-acether binding
A time course of [3H]PAF-acether binding to intact human platelets at concentrations .0.1 nM showed an increase of radioactivity associated with the platelets during 60-80min before equilibrium was reached ( Fig. 1) (Fig.   3 ) of the data between 0.02 and 0.9nM
in which kobs. (the observed rate constant) stands for k + k2. Fig. 4(a) (Table 1) .
In agreement with these observations were the results of a second type of experiments. This consisted of a first incubation (30min) with nonradiolabelled PAF-acether followed by gel-filtration through Sepharose 2B, and a second incubation with PAF-acether (30min), which was now radiolabelled. A high dose of PAF-acether (1 gM) in the first step prevented all specific binding in the second step, indicating that all receptors had been irreversibly changed during the first incubation. A low dose of [3H]PAF-acether (0.4nM) in the first step reduced the binding in the second step (Fig.  5) , suggesting that less binding sites were available in these platelets.
Metabolism of [3H]PAF-acether
As illustrated in Table 2 , incubation of platelets with high concentrations of [3H]PAF-acether resulted in the formation of a 3H-labelled fraction with the chromatographic properties, on highperformance t.l.c., of an alkyl(long-chain)acylphosphocholine (Pieroni & Hanahan, 1983 Platelet responses induced by PAF-acether In order to investigate whether the formation of a PAF-acether-receptor complex had any relevance for the initiation of platelet responses, the effect of PAF-acether binding on several cellular processes was studied. Platelets were incubated with PAF-acether under the conditions where the receptor studies had been carried out (0.5 nm-PAFacether, 220C), except for the aggregation studies, where stirring was required. PAF-acether triggered shape-change, but no optical aggregation occurred unless fibrinogen was added (Table 3) . The disappearance of single platelets in stirred suspensions was already considerable in the presence of PAF-acether alone, but further extended by the addition of fibrinogen. Table 4 illustrates that platelet stimulation with 0.5 nm-PAF-acether at 220C triggers the exposure of the fibrinogen receptor. In accordance with other reports (Niewiarowski et order to avoid cell activation and secretion (Fine et al., 1976 (Hwang et al., 1983 ). This binding is fully reversible after 15min, whereas intact platelets form an irreversible complex at a velocity that increases at higher doses of PAF-acether. Probably the formation of an irreversible complex requires an intact cellular apparatus, by analogy with the binding of fibrinogen to its receptor on activated platelets, which also becomes irreversible in time (Marguerie et al., 1980) . Partial saturation of the receptors with unlabelled PAF-acether followed by gel filtration and incubation with a second dose of (Heldin et al., 1982) remains to be elucidated.
The affinity of PAF-acether binding is 105 times higher than that for ADP (Legrand et al., 1980 ) and 4-20 times higher than for thrombin (Siegl et al., 1979) , which is one of the most potent agonists in platelet activation. The fact that PAF-acether binding does not require Ca2+ ions limits the role of this cation to the formation of fibrinogen bridges that link one platelet to another (Marguerie & Plow, 1982) . Platelets pretreated with PAF-acether become desensitized for a second dose of PAF-acether, a property that is relieved by the inclusion of adrenaline (epinephrine) in the second activation step (Vargaftig et al., 1982b) . One might speculate that desensitization is the result of the formation of irreversible PAFacether-receptor complexes. However, no effect of adrenaline (1 Mm) was found on the binding kinetics (E. Kloprogge, unpublished work), suggesting that the role of adrenaline is not at the receptor level.
Although the present data link receptor occupancy to platelet responses, an additional role for PAF-acether uptake and metabolism cannot be ruled out. At 37°C, [3H]PAF-acether uptake surpasses receptor binding severalfold, making receptor studies at this temperature quite difficult. Exogenous PAF-acether is converted by platelets into lyso-PAF-acether via a reaction catalysed by an acetyl hydrolase . The next enzyme in this sequence, acyl-CoA: l-acyl-snglycero-3-phosphocholine acyltransferase, is present in platelet microsomes McKean et al., 1982) and able to form alkylacylphosphocholine, an analogue with a long-chain acyl group at the sn-2 position. In our studies we found a 3H-labelled phospholipid with the chromatographic properties of a phosphatidylcholine after prolonged incubation with high (>1 nM) amounts of [3H]PAF-acether. A similar fraction has been found by Pieroni & Hanahan (1983) , who concluded that its formation was too slow to be important in platelet activation. A definite conclusion regarding the relative roles of receptor occupancy and uptake and metabolism awaits the development of a specific inhibitor for the uptake site that leaves the receptor site unaltered.
